Related Experiment Video

Updated: May 27, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents

Andreia Costa1, Sabine Tejpar, Hans Prenen

  • 1Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium.

Targeted Oncology
|November 25, 2011
PubMed

Insights

Targeted anti-epidermal growth factor receptor (EGFR) agents can cause hypomagnesaemia and hypocalcaemia. This review details the mechanisms, clinical findings, and management of these electrolyte disorders in cancer patients.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Targeted anti-epidermal growth factor receptor (EGFR) agents are crucial in cancer therapy.
  • These therapies, especially monoclonal antibodies, can lead to electrolyte disturbances like hypomagnesaemia and hypocalcaemia.
  • Early recognition of magnesium deficiency is challenging, yet severe cases can manifest as cardiac arrhythmias or convulsions.

Purpose of the Study:

  • To review clinical trial findings on hypomagnesaemia induced by anti-EGFR agents.
  • To discuss the underlying mechanisms of EGFR inhibitor-related electrolyte disorders.
  • To outline treatment strategies for hypomagnesaemia in patients receiving anti-EGFR therapy.

Main Methods:

  • Literature review of peer-reviewed journals.
  • Analysis of clinical trial data.
  • Discussion of pharmacological mechanisms.

Main Results:

  • Anti-EGFR agents can cause urinary magnesium and calcium wasting due to inhibition of the transient receptor potential cation channel, subfamily M, member 6 (TRPM6).
  • The risk of hypomagnesaemia correlates with treatment duration.
  • This toxicity is reversible, with magnesium levels typically normalizing 4-6 weeks after treatment cessation.

Conclusions:

  • Hypomagnesaemia is a significant, albeit reversible, side effect of anti-EGFR targeted therapies.
  • Understanding the mechanism involving renal EGF/EGFR expression and TRPM6 is key to managing this toxicity.
  • Prompt identification and management are essential for patient safety during cancer treatment.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...